Gilead Sciences seeks to rescind Orphan Drug Designation for remdesivir for Covid-19

Gilead Sciences has asked the US FDA to revoke the designation after an outcry was raised over the potential for exclusivity for the experimental pandemic treatment. Gilead is confident that it can maintain an expedited timeline in seeking regulatory review of remdesivir.


Biospace Inc.